


Crohn's Disease Market Size to Reach USD 12,052.2 Million by 2035 - Epidemiology Report by IMARC Group

The report provides a detailed analysis of the current Crohn's disease marketed drugs and late-stage pipeline drugs, Advancement in Treatment.

BROOKLYN, NY, UNITED STATES, June 25, 2025 /EINPresswire.com/ -- The Crohn's disease market size reached a value of USD 8,587.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 12,052.2 Million by 2035, exhibiting a growth rate (CAGR) of 3.12% during 2025-2035. The rising prevalence of enteric infections, which lead to inflammation and damage to the intestinal lining, is primarily driving the Crohn's disease market.



The Crohn's disease market, pertaining to the treatment of this chronic inflammatory bowel disease, is a major Adaptium's investment and growth. Symptoms like stomach pain, hardcore diarrhea, and tiredness are caused by inflammation in different parts of the digestive system. This inflammation invariably affects the quality of life for a patient. An ongoing market shift is high-degree precision therapies. Moderate-to-severe cases still rely on anti-TNF biologics, but newer biologics such as ustekinumab and risankizumab are expanding with interleukin targeting. In addition to this, small molecules like JAK stimulators are being taken orally. These drugs could improve patient compliance to maintaining long-term treatments because they are easier to use. The growing development of biosimilars is critical for lower healthcare costs and providing advanced biologic treatments to more patients around the world. Moreover, biosimilars assist in chronic disease therapeutics through population-specific genetic profiling and biomarkers enabling customized medicine. Early diagnosis and intervention can increase the chances of having effective and precise treatment options available during the initial stages of a disease. Another innovative form is regenerative therapy with stem cells for complex perianal fistula gaps.

The primary reason why people have inflammatory bowel diseases like Crohn's disease is also linked with one's population alongside inflating demand for new and better medication fueling faster market growth. Seen from above, more accurate diagnostics aid help these individuals accurately track their diseases progress over time improving outcomes significantly.

There's still lots to do in terms of research and development, but there are innovative treatments that have been made available to address Crohn's disease. The growing awareness globally as well as healthcare access especially in developing areas is helping the market grow. Although they persist these challenges like high treatment costs and diagnostic delays, there is hope with new innovation and a broadening understanding which promises better patient care everywhere.

Request a PDF Sample Report: <https://www.imarcgroup.com/crohns-disease-market/requestsamplereport>

The report also provides a detailed analysis of the current Crohn's disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the Crohn's disease market has been studied in the report with the detailed profiles of the key players operating in the market.

- Takeda Oncology
- Biogen/Perrigo
- AbbVie/AstraZeneca
- AbbVie/Boehringer Ingelheim
- UCB

Pfizer
AstraZeneca
Bristol-myers squibb
Janssen Biotech
Eli Lilly and Company
RedHill Biopharma Ltd.
Abivax

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

IMARC Group Offers Other Reports:

Agoraphobia Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/821443845/agoraphobia-market-epidemiology-report-2025-2035-drug-pipeline-treatment-trends-rising-incidence-prevalence>

Fabry Disease Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/823036764/fabry-disease-treatment-market-size-2025-2035-epidemiology-trends-drug-pipeline>

ANCA Vasculitis Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/820354434/anca-vasculitis-market-size-epidemiology-trends-treatment-and-forecast-2025-2035>

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Elena Anderson
IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/825424751>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.